Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01484262|
Recruitment Status : Completed
First Posted : December 2, 2011
Last Update Posted : November 17, 2016
|Condition or disease||Intervention/treatment|
|Diabetes Diabetes Mellitus, Type 2||Drug: liraglutide Drug: insulin|
|Study Type :||Observational|
|Actual Enrollment :||1344 participants|
|Official Title:||Liraglutide or Insulin in Real Life Usage in Patients With Diabetes Mellitus Type 2|
|Study Start Date :||November 2011|
|Actual Primary Completion Date :||October 2014|
|Actual Study Completion Date :||October 2014|
Patients will be treated according to routine clinical practice at the discretion of the treating physician according to current labelling.
Any insulin in any device available on the market may be used by patients as part of routine clinical practice according to current labelling.
- Diabetes-related quality of life assessed by ADDQoL (Audit of Diabetes-Dependent Quality of Life) [ Time Frame: At the end of the observational period (52 weeks) ]
- Total cost of patient's diseases [ Time Frame: At the end of the observational period (52 weeks) ]
- Total cost of patient education [ Time Frame: At the end of the observational period (52 weeks) ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01484262
|Novo Nordisk Investigational Site|
|Mainz, Germany, 55127|
|Study Director:||Global Clinical Registry (GCR, 1452)||Novo Nordisk A/S|